Category: Melanoma

Home / Established Year

Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma
, , , ,

Nivolumab is approved by the FDA for adjuvant treatment of Stage IIB/C melanoma

Nov 2023: Nivolumab (Opdivo, Bristol-Myers Squibb Company) was granted approval by the Food and Drug Administration as an adjuvant therapy for Stage IIB/C melanoma in patients 12 years of age and older who had undergone complete..

, , , , , , ,

First LAG-3-Blocking antibody combination, Opdualag™ (nivolumab and relatlimab-rmbw), is approved by FDA for patients with unresectable or metastatic melanoma

April 2022: The US Food and Drug Administration (FDA) has approved Opdualag (nivolumab and relatlimab-rmbw), a new, first-in-class fixed-dose combination of nivolumab and relatlimab administered as a single intravenous infusion, f..

, , , ,

Tebentafusp-tebn is approved for unresectable or metastatic uveal melanoma

March 2022: Tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, has been licenced by the Food and Drug Administration for HLA-A*02:01-positive adult patients with unresectab..

, , , , , , , ,

Melphalan flufenamide receives approval from the FDA for relapsed or refractory multiple myeloma

August 2021: Melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone has been granted accelerated approval by the Food and Drug Administration for adult patients with relapsed or refractory multiple myel..

Pembrolizumab
, , , , ,

Pembrolizumab is approved by FDA for adjuvant treatment of melanoma

On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after full resection. The approval ..

, , ,

Bariatric surgery can reduce the risk of melanoma

In addition to rapid and lasting weight loss and other health benefits, bariatric surgery is now associated with a 61% reduced risk of malignant melanoma, which is the deadliest skin cancer most closely associated with excessive s..

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy